By Nicole Bell, MBA, CEO of Galaxy Diagnostics, and Bonnie Crater, Co-Founder of the Center for Lyme Action and Bay Area Lyme Foundation. Moderated by Dr. Amy Offutt, MD, Immediate Past President of the International Lyme and Associated Diseases Society (ILADS) Summary: Research published between 2024 and 2026 sharpens understanding of why early Lyme disease… Continue reading Early Lyme Disease Testing: What Clinicians Need to Know
By Dr. Myriah Hinchey, ND, FMAPS, FILADS, Medical Director, TAO Vitality | Founder, LymeCore Botanicals Summary: The acute window following a tick bite is the highest-yield period for early detection and also the period when standard diagnostic approaches are least reliable. A sound tick bite testing protocol for this window must account for the biological… Continue reading After the Tick Bite: What Clinicians Need to Know
By Jennifer C. Miller, PhD, Vice President of Clinical & Scientific Operations, Galaxy Diagnostics Summary: Babesia is an intraerythrocytic parasite that has become one of the most persistent diagnostic blind spots in tick-borne medicine. Despite growing clinical recognition, standard testing methods frequently fail to detect Babesia in chronic presentations, where parasitemia is low, symptoms… Continue reading The Babesia Detection Problem: Why Results Differ in Low-Level Parasitemia
By Edward B. Breitschwerdt, DVM, Co-Founder, Galaxy Diagnostics, and Distinguished Professor Emeritus of Internal Medicine and Infectious Diseases, NC State University College of Veterinary Medicine Summary: Bartonella is one of the most diagnostically overlooked pathogens in clinical medicine, not because it is rare, but because the standard tools used to find it (including both… Continue reading Bartonella: The Blind Spot Pathogen Clinicians Can’t Afford to Miss
Galaxy Diagnostics and Virginia Tech Unite to Advance Testing for Lyme Disease By Nicole Danielle Bell, CEO of Galaxy Diagnostics and author of What Lurks in the Woods When a Test Fails a Patient When diagnostics fail patients, the consequences are real. I’ve lived it. My husband tested negative using the current standard-of-care test for… Continue reading Two LymeX Innovators, One Mission: Better Answers for Patients
Galaxy Diagnostics and Virginia Tech Unite to Strengthen Direct Detection Approaches for Lyme Disease By Nicole Danielle Bell, CEO of Galaxy Diagnostics and author of What Lurks in the Woods The Diagnostic Uncertainty Clinicians Face Clinicians evaluating patients with suspected tick-borne disease routinely manage diagnostic uncertainty. Prior exposure, immune variability, and timing-dependent antibody responses can… Continue reading Two LymeX Innovators, One Mission: Advancing Reliable Lyme Diagnostics
